The AI is only as good as the knowledge behind it.
Mednet AI is a clinical assistant built on a foundation ten years in the making — 40,000+ physicians and 3,400 academic experts.
➝ www.themednet.org?utm_source=b...
#MednetAI #MedSky #AIinHealthcare
"Game-changer compared to traditional LLMs."
— Panicker Renni Robinson, MD, Cardiology Fellow
That's what Mednet AI was built for. Evidence + real expert opinion, combined. Free for all US physicians. ➝ www.themednet.org?utm_source=b...
#MednetAI #MedSky #AIinHealthcare
Most clinical assistants answer: what does the research say?
Mednet AI answers: what do experienced physicians actually do?
There's a difference. ➝ www.themednet.org?utm_source=b...
#MednetAI #MedSky #AIinHealthcare
We've got big news!!
Mednet AI is now live — a clinical assistant informed by 10 years of real-world conversations from 40,000+ physicians, combined with the best of medical research.
Free for all US physicians. Ask us anything. ➝ tinyurl.com/2jdzf75x
#MednetAI #AI #AIinHealthcare #ClinicalAI
@themednet.bsky.social has a new search ability making it even easier to find answers from colleagues. If not answered in the past, ask a new question to get answers from experts you trust: blog.themednet.org/the-new-medn...
New #LetsTalkID! @paulsaxmd.bsky.social talks w/ @pjpass.bsky.social, a med-peds ID physician at @dartmouthhealth.bsky.social & ID editor of @themednet.bsky.social, about finding trusted expert guidance beyond AI & how clinician communities help shape real-world practice.
Transcript: bit.ly/3NcrZhx
New on IDSA - Paul Sax, MD interviews Patrick Passarelli, MD (Dartmouth-Hitchcock; ID editor @Mednet) on getting expert guidance beyond AI + what makes a great clinical question.
www.idsociety.org/multimedia/p...
#MedEd #InfectiousDiseases
In mCRPC patients who had an initial response to Pluvicto but progress within 12 months, where do you position PSMA radioligand retreatment relative to other next-line systemic options in your sequencing strategy?
www.themednet.org/v2/programs/199/questions?mode=question&questionId=27604"
Link to relevant Q&A:
What criteria are you using for retreatment with Pluvicto (Lu-177) in those who maintain a good performance status and appropriate lab work?
www.themednet.org/v2/programs/199/questions?mode=question&questionId=20197"
The American Society for Radiation Oncology (ASTRO) #MRPTS26 plenary session on Radiopharmaceutical Retreatment (Plenary II) just concluded.
Dr. Ana Kiess is answering questions now on theMednet.
Head to the Q&A → www.themednet.org/v2/programs/199/questions?mode=question&questionId=20197
Link to relevant Q&A:
Does the possibility of future Lu-177–PSMA therapy change your current threshold to offer earlier metastasis-directed RT in oligometastatic prostate cancer?
www.themednet.org/v2/programs/199/questions?mode=question&questionId=27603
Link to relevant Q&A:
Can you give Pluvicto with concurrent palliative EBRT?
www.themednet.org/v2/programs/199/questions?mode=question&questionId=17105
The American Society for Radiation Oncology (ASTRO) #MRPTS26 plenary session on Clinical Outcomes among Patients Treated with Lu-PSMA-617 and EBRT for Oligometastatic Prostate Cancer just concluded.
Dr. Neil K Taunk is answering questions now on theMednet.
Links to relevant Q&A:
When selecting mCRPC patients for Pluvicto, which baseline variables do you find most useful or predictive of potential hematologic toxicity? - www.themednet.org/v2/programs/199/questions?mode=question&questionId=27602
Links to relevant Q&A:
Do you modify dosing and monitoring of Lu-177–PSMA therapy for patients with prior large-field RT involving substantial active marrow compared with patients who only had focal bone SBRT? - www.themednet.org/v2/programs/199/questions?mode=question&questionId=27601
The American Society for Radiation Oncology (ASTRO) #MRPTS26 plenary session on Hematologic Toxicity Outcomes of Lu-PSMA-617 in Patients Previously Treated with EBRT for Oligometastatic Disease just concluded.
Drs. Neil K Taunk & Krishnan R Patel are answering questions now on theMednet.
Links to relevant Q&A:
How do you sequence Pluvicto vs docetaxel in a fit, chemotherapy-naïve patient with high-volume PSMA-avid mCRPC progressing on an ARPI? - www.themednet.org/v2/programs/199/questions?mode=question&questionId=27599
Links to relevant Q&A:
For patients starting Pluvicto, do you have patients stop their ARPI? - www.themednet.org/v2/programs/199/questions?mode=question&questionId=26213
ASTRO plenary session on Safety and Efficacy of Lu-177 PSMA-617 Versus Established Therapies in mCRPC: Pooled Evidence from Randomized Phase II/III Trials just concluded.
Dr. John Nikitas is answering questions now on theMednet.
Head to the Q&A → www.themednet.org/v2/programs/199/questions
Join the conversation to share perspectives, ask follow-up questions, and see how others are interpreting the findings.
Join the Conversation: www.themednet.org/v2/programs/...
Keep the Conversation Going with theMednet
We’re hosting dedicated Q&A on theMednet for studies featured in this week’s Plenary and Clinical Trials sessions at the ASTRO 2026 Multidisciplinary Radiopharmaceutical Therapy Symposium in Palm Desert, CA.
#MRPTS26
From Dr. Paul Sax’s NEJM blog (HIV and ID Observations): when the question isn’t “What do the guidelines say?” but “What would you actually do?”
Read the blog here: blogs.nejm.org/hiv-id-obser...
#InfectiousDiseases #NEJM #theMednet
Meet the team behind theMednet
Introducing Dan Ricotta, MD — Medical Director, General Internal Medicine and Geriatrics at theMednet, and Associate Professor of Medicine at Harvard Medical School.
Join the peer-to-peer conversation on theMednet.org.
How do you explain the use of an AI scribe to patients?
Join the Conversation: www.themednet.org/v2/question/...
#Psychiatry #HealthAI #DigitalHealth #PatientPrivacy #ClinicalDocumentation #PatientExperience